{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["80(6)"],"submitter":["Matsubara N"],"journal":["Cancer chemotherapy and pharmacology"],"pagination":["1073-1077"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6828099"],"repository":["biostudies-literature"],"pubmed_title":["Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer."],"pmcid":["PMC6828099"],"pubmed_authors":["Hosono A","Sasaki M","Yajima Y","Yasuda M","Hashizume K","Matsubara N","Zurth C","Mukai H","Uemura M","Onomura M"],"additional_accession":[]},"is_claimable":false,"name":"Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.","description":null,"dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2025-04-22T17:38:07.904Z","creation":"2025-04-06T02:08:44.814Z"},"accession":"S-EPMC6828099","cross_references":{"pubmed":["29063294"],"doi":["10.1007/s00280-017-3433-3"]}}